ArticleScientific reports2025
LncRNA DRAIC facilitates the progression of renal cell carcinoma by modulting the microRNA-145-3p/ABRACL pathway signaling.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Adaptation of Non-Invasive Cancer Cells to 3D Collagen I Microenvironment Induces Transcriptional Reprogramming Accompanied by a More Complex RNA Landscape.International journal of molecular sciences · 2026Article
- Long Non-Coding RNAs in Pathogenesis of Renal Cell Carcinoma: Epigenetic Regulation, Signaling Pathways, and Therapeutic Strategies.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aims to elucidate the functional mechanisms of LncRNA DRAIC in renal cell carcinoma, particularly its regulation of tumor progression via microRNA-145-3p and ABRACL. The downstream targets of LncRNA DRAIC were predicted using databases, and their interactions with microRNA-145-3p were experimentally validated. The effects of LncRNA DRAIC overexpression on the proliferation, invasion, and migration of renal carcinoma cells were evaluated using stable cell lines, CCK-8 assays, Transwell assays, subcutaneous tumor transplantation in nude mice, and in vivo fluorescence imaging experiments. Techniques such as Western blot and RT-PCR were utilized to monitor the expression levels of ABRACL under the regulation of LncRNA DRAIC, further confirming its role in renal carcinoma cell functions. Overexpression of LncRNA DRAIC significantly enhanced the proliferation, invasion, and migration capabilities of renal carcinoma cells. Moreover, it was discovered that LncRNA DRAIC regulates the expression of ABRACL by modulating microRNA-145-3p, thereby affecting the functionality of renal carcinoma cells. This reveals the critical mechanisms of LncRNA DRAIC in renal cell carcinoma, where it governs tumor cell biology through microRNA-145-3p and ABRACL, offering new targets and theoretical foundations for the treatment of renal cell carcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.